Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients.
angiogenesis
body mass index
breast cancer
menopausal status
molecules
subtype
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Jul 2022
14 Jul 2022
Historique:
received:
06
05
2022
revised:
04
07
2022
accepted:
07
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Angiogenesis is a hallmark of breast cancer (BC) and is mediated by the vascular endothelial growth factor (VEGF) signaling axis. It is regulated by different proangiogenic factors, including platelet-derived growth factor-CC (PDGF-CC) and heparin-binding EGF-like growth factor (HB-EGF), as well as co-receptors, such as neuropilin-1, which could have prognostic implications in BC patients. We assessed the serum levels of VEGF, HB-EGF, PDGF-CC and neuropilin-1 in 205 patients with early BC (invasive, VEGF serum levels were significantly higher in patients with invasive versus ductal carcinomas in situ. PDGF-CC serum concentrations varied among BC molecular subtypes. Furthermore, we observed a differential expression of most biomarkers between overweight/obese (body mass index (BMI) ≥ 25 kg/m The serum concentrations of angiogenic molecules differ among breast cancer molecular subtypes and are affected by the BMI and menopausal status, which could have possible clinical or prognostic implications.
Sections du résumé
BACKGROUND
BACKGROUND
Angiogenesis is a hallmark of breast cancer (BC) and is mediated by the vascular endothelial growth factor (VEGF) signaling axis. It is regulated by different proangiogenic factors, including platelet-derived growth factor-CC (PDGF-CC) and heparin-binding EGF-like growth factor (HB-EGF), as well as co-receptors, such as neuropilin-1, which could have prognostic implications in BC patients.
PATIENTS AND METHODS
METHODS
We assessed the serum levels of VEGF, HB-EGF, PDGF-CC and neuropilin-1 in 205 patients with early BC (invasive,
RESULTS
RESULTS
VEGF serum levels were significantly higher in patients with invasive versus ductal carcinomas in situ. PDGF-CC serum concentrations varied among BC molecular subtypes. Furthermore, we observed a differential expression of most biomarkers between overweight/obese (body mass index (BMI) ≥ 25 kg/m
CONCLUSION
CONCLUSIONS
The serum concentrations of angiogenic molecules differ among breast cancer molecular subtypes and are affected by the BMI and menopausal status, which could have possible clinical or prognostic implications.
Identifiants
pubmed: 35887839
pii: jcm11144079
doi: 10.3390/jcm11144079
pmc: PMC9323050
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Growth Factors. 2019 Aug;37(3-4):131-145
pubmed: 31542979
PLoS One. 2014 Jul 15;9(7):e102176
pubmed: 25025175
Int J Cancer. 2010 Dec 1;127(11):2707-17
pubmed: 20499311
Oncotarget. 2016 Aug 23;7(34):54723-54732
pubmed: 27351129
Breast Cancer Res. 2005;7(5):R788-95
pubmed: 16168125
Breast Cancer Res Treat. 2018 Jun;169(2):231-241
pubmed: 29380207
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Cancer Cell. 2009 Jan 6;15(1):21-34
pubmed: 19111878
Oncol Rep. 2017 Sep;38(3):1886-1894
pubmed: 28714000
Cell Adh Migr. 2012 Nov-Dec;6(6):547-53
pubmed: 23257828
Eur J Pharmacol. 2021 Mar 15;895:173868
pubmed: 33460613
Target Oncol. 2015 Jun;10(2):189-98
pubmed: 25185646
Hum Pathol. 2008 Dec;39(12):1835-43
pubmed: 18715621
Life Sci. 2015 Oct 15;139:16-23
pubmed: 26297445
In Vivo. 2020 Sep-Oct;34(5):2641-2646
pubmed: 32871794
Pathobiology. 2011;78(5):253-60
pubmed: 21849806
Breast Cancer Res Treat. 2011 Aug;129(1):175-84
pubmed: 21390493
Prog Mol Biol Transl Sci. 2017;151:1-32
pubmed: 29096890
Cancer Biol Ther. 2011 May 15;11(10):910-7
pubmed: 21451264
Cancer Biother Radiopharm. 2016 Apr;31(3):85-90
pubmed: 27093342
Ann Oncol. 2009 Oct;20(10):1615-7
pubmed: 19690059
Ann Oncol. 2009 Oct;20(10):1639-46
pubmed: 19549711
J Clin Oncol. 2005 Mar 10;23(8):1782-90
pubmed: 15755986
Biochem Biophys Res Commun. 2002 Apr 5;292(3):781-6
pubmed: 11922634
Front Cell Dev Biol. 2020 Jul 17;8:662
pubmed: 32766254
BMC Cancer. 2009 Jul 07;9:220
pubmed: 19580679
Mol Cancer Res. 2013 May;11(5):506-17
pubmed: 23443317
Clin Transl Oncol. 2019 Sep;21(9):1250-1259
pubmed: 30788837
J Cancer. 2020 May 18;11(15):4474-4494
pubmed: 32489466
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737